McKesson Co. (NYSE:MCK) Shares Bought by Quantbot Technologies LP

Quantbot Technologies LP increased its stake in shares of McKesson Co. (NYSE:MCK - Free Report) by 60.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 20,201 shares of the company's stock after purchasing an additional 7,638 shares during the period. McKesson accounts for approximately 0.4% of Quantbot Technologies LP's investment portfolio, making the stock its 27th biggest position. Quantbot Technologies LP's holdings in McKesson were worth $11,513,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. FMR LLC lifted its position in shares of McKesson by 17.3% in the third quarter. FMR LLC now owns 2,968,239 shares of the company's stock valued at $1,467,557,000 after acquiring an additional 438,423 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in McKesson by 55.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,189,377 shares of the company's stock valued at $588,048,000 after purchasing an additional 425,875 shares in the last quarter. Janus Henderson Group PLC boosted its stake in McKesson by 126.8% during the 3rd quarter. Janus Henderson Group PLC now owns 574,440 shares of the company's stock worth $283,903,000 after purchasing an additional 321,119 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of McKesson during the fourth quarter worth $178,397,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of McKesson in the fourth quarter valued at about $128,125,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

McKesson Price Performance

Shares of MCK stock traded down $1.15 during trading hours on Wednesday, hitting $662.45. The company had a trading volume of 737,849 shares, compared to its average volume of 801,209. The stock has a market capitalization of $83.02 billion, a PE ratio of 30.33, a price-to-earnings-growth ratio of 1.29 and a beta of 0.52. The company's fifty day moving average is $619.05 and its 200 day moving average is $576.50. McKesson Co. has a fifty-two week low of $464.42 and a fifty-two week high of $670.79.

McKesson (NYSE:MCK - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $8.03 EPS for the quarter, missing analysts' consensus estimates of $8.60 by ($0.57). McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. Equities analysts forecast that McKesson Co. will post 32.77 earnings per share for the current year.

McKesson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Monday, March 3rd will be given a dividend of $0.71 per share. The ex-dividend date of this dividend is Monday, March 3rd. This represents a $2.84 annualized dividend and a dividend yield of 0.43%. McKesson's dividend payout ratio is presently 13.00%.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on MCK shares. Bank of America lowered their price target on shares of McKesson from $680.00 to $650.00 and set a "buy" rating on the stock in a research report on Monday, January 6th. Morgan Stanley upped their price target on McKesson from $612.00 to $642.00 and gave the company an "overweight" rating in a research report on Tuesday, December 17th. Mizuho assumed coverage on McKesson in a research report on Wednesday, December 4th. They set a "neutral" rating and a $630.00 price objective on the stock. StockNews.com lowered McKesson from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th. Finally, Wells Fargo & Company lifted their price target on McKesson from $641.00 to $691.00 and gave the stock an "equal weight" rating in a report on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $649.36.

Insider Transactions at McKesson

In other McKesson news, CEO Brian S. Tyler sold 8,961 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $600.66, for a total transaction of $5,382,514.26. Following the sale, the chief executive officer now directly owns 69,625 shares in the company, valued at $41,820,952.50. This represents a 11.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Leann B. Smith sold 188 shares of the business's stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $609.59, for a total transaction of $114,602.92. Following the completion of the transaction, the executive vice president now owns 1,051 shares of the company's stock, valued at approximately $640,679.09. This trade represents a 15.17 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,689 shares of company stock valued at $11,187,351. 0.11% of the stock is currently owned by corporate insiders.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.